Select your language

ISSN 1995-5537

«Біотехнологія» journal V. 5, No. 6, 2012
Р. 73-77, Bibliography 12, Ukrainian.
Universal Decimal classification: 577. 112.7:616


Y. Ya. Kit, R. O. Bilyy, T. V. Skorokhoda, N. M. Boiko, N. S. Korniy,
N. E. Mitina, A. S. Zaichenko, R. S. Stoika

Institute of Cell Biology of National Academy of Sciences of Ukraine, Lviv
Lviv Polytechnic National University

With the aim to enhance therapeutic effectiveness, a drug doxorubicin was previously conjugated with surface-active water-soluble synthetic oligomer TF3 and water-soluble TF3-Dox conjugates were obtained possessing high cytotoxic activity towards tumor cells in vitro. As the therapeutic use of anticancer drugs is performed by intravenous administration, the purpose of the work was to determine the peculiarities of TF3 Docks interaction with proteins and human blood cells. Peripheral human blood was incubated with TF3-Dox or with pure doxorubicin, as control, afterwards blood was separated for plasma and cellular components by centrifugation. The affinity of doxorubicin and TF3-Dox to blood cells was evaluated by fluorescent microscopy. Plasma proteins were separated by electrophoresis in 1% agarose gel and detected via UV-light illumina tion. It was found that TF3-Dox unlike doxorubicin are able to be selectively accumulated in nucleated blood cells as well as to form stable complexes with serum albumin. Formation of such complexes can facilitate their endocytosis by nucleated blood cells. Obtained data suggest the perspectives of the use of TF3 carrier for targeted delivery of doxorubicin during onco-haematologic diseases.

Key words: human blood cells, sera proteins, nano scale doxorubicin conjugates, interaction.

© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2008